Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_assertion type Assertion NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_head.
- NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_assertion description "[We observed subsequent loss of type II TGFbeta receptor (TBR2) expression in metastatic renal cell carcinomas [RCC }.We propose that loss of TBR3 is necessary for RCC carcinogenesis, and loss of TBR2 leads to acquisition of a metastatic phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_provenance.
- NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_assertion evidence source_evidence_literature NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_provenance.
- NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_assertion SIO_000772 12970754 NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_provenance.
- NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_assertion wasDerivedFrom lhgdn-20090331 NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_provenance.
- NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_assertion wasGeneratedBy ECO_0000203 NP192806.RA69hAdHPxlop2qWD47C5dQiED3uloq_lr8V5fnPWvoYA130_provenance.